Columbia Hamilton Lane and Bahnsen file for interval funds with opposite private-asset sourcing

Two interval fund registrations reached the shelf in September, each with the same question answered from opposite ends: whose funds hold the private assets. The Columbia Hamilton Lane Growth Innovation Fund plans a portfolio split between 40% and 60% public equities and 40% to 60% private asset investments, ranges the prospectus says may vary over time, and expects at least 40% of its net assets exposure to arrive through underlying investment funds that Hamilton Lane manages. The Bahnsen Group Alternative Core Solutions Fund would instead build its portfolio from pooled vehicles—registered closed-end and open-end funds, private investment funds, and other investment vehicles the prospectus gathers under a single label, "Investment Funds."

The September tally from Interval Fund Tracker, published at the start of October, put the month at those two N-2 registrations, a small number, but the more useful comparison is how each sponsor filled the same interval container: one routed exposure to a single platform, the other assembled a portfolio of other managers' funds.

The Columbia filing is the more concentrated of the two, seeking capital appreciation by pairing publicly traded equity securities with private asset investments and targeting companies that Columbia Management believes have long-term growth potential or that support, benefit from, or drive innovation through new technologies, products, services, processes, business models, or markets. Its public equity sleeve generally holds U.S. and foreign growth companies in the market-capitalization range of the Russell 3000 Growth Index, while the private sleeve ranges wider, taking direct and indirect exposure to early-stage, venture capital, growth equity, and buyout companies alongside private fund investments, secondaries, co-investments, joint ventures, and other private markets transactions.

The two portfolio floors nest. Private assets can sit at 40% of the fund while Hamilton Lane exposure can also sit at 40% of net assets, so at the low end the entire private sleeve could live inside Hamilton Lane vehicles, with direct positions, secondaries, and co-investments layered on as the sleeve stretches toward 60%.

The disclaimer deserves the pause. Hamilton Lane is not the fund's adviser, sub-adviser, sponsor, promoter, principal underwriter, or affiliate, the prospectus states, even though its vehicles are expected to carry that 40% of net assets exposure, and a firm reporting $141.8 billion in registered assets per IVF's records is supplying the private sleeve without taking on the corporate roles that ordinarily accompany managing someone else's money.

The arrangement matches what this publication described when the wrapper first appeared on the shelf in September: a distribution channel into funds Hamilton Lane already runs, extended by a sponsor that gets private-markets sourcing it would otherwise have to build.

The share classes are set even where the fee is not: four classes—Class A, FoundersA, FoundersInst, and Institutional—each with a $10,000 initial minimum per account and no minimum on subsequent purchases. Class A and FoundersA carry a sales load of up to 3.0%, while Class Inst and FoundersInst carry no fund-imposed sales charge, and the management fee is listed as TBD.

The Bahnsen filing inverts the arrangement, seeking current income and, secondarily, long-term capital appreciation by investing directly or indirectly in registered closed-end and open-end funds, private investment funds, and other investment vehicles—the "Investment Funds"—which may represent all or a substantial portion of the portfolio at any given time.

Manager selection is the product: the strategy centers on choosing underlying managers and general partners across private and alternative investment strategies, and the fund may invest in private markets funds and co-investments originated, serviced, or underwritten by those managers, with alternative credit, private equity, hedged strategies, and direct credit strategies among the possibilities the prospectus lists.

The private exposure therefore arrives as fund interests rather than positions in companies the sponsor picks itself—Columbia's sleeve is written to hold private companies directly, Bahnsen's to hold other managers' funds.

The two do not chase the same client either: Columbia's mandate is capital appreciation behind a growth-innovation thesis, Bahnsen's leads with income, and what they share is the interval structure and the shelf it sits on.

This publication has argued that sponsors already hold the demand curve they need—Hamilton Lane's survey of 390 advisors being the evidence—and that the shelf, not the pitch, decides which vehicles absorb the allocation. September added two names to that shelf: one routes at least 40% of its net assets exposure back into funds run by a single manager, the other selects underlying managers and general partners across private and alternative strategies. On cost, the record is thin, with the Columbia filing carrying a load of up to 3.0% on two of its four classes and the management fee unfilled, while the September tally reports no fee terms for the Bahnsen fund. That is the column an advisor comparing the two would reach for first, and on these documents it is blank.